This is a Phase 1, open-label, multi-center study to determine the pharmacokinetics and
safety of intravenous Eravacycline in Children with Suspected or Confirmed Bacterial
Infection. Male and Female subjects from 8 to <18 years of age who fulfill the
inclusion/exclusion criteria will be enrolled in this study.